Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1C7HT | ISIN: EE3100007857 | Ticker-Symbol:
1-Jahres-Chart
COOP PANK AS Chart 1 Jahr
5-Tage-Chart
COOP PANK AS 5-Tage-Chart
GlobeNewswire (Europe)
151 Leser
Artikel bewerten:
(1)

Coop Pank AS results for July 2024

Finanznachrichten News

Coop Pank's financial results in July 2024:

  • In July, number of the bank's clients increased by 1,600 and number of active clients increased by 600. By the end of the month number of clients reached 197,700 and number of active clients reached 90,100. Over the year, customer base has grown by 16%.
  • Volume of the bank's customer deposits increased by 64 million euros, reaching 1.80 billion euros by the end of month. Deposits of corporate customers increased by 33 million euros and deposits of private customers remained stable. The volume of deposits attracted from international platforms increased by 31 million euros. Over the year, volume of bank deposits has grown by 1%.
  • The bank's loan portfolio increased by 16 million euros and reached 1.64 billion euros by the end of month. Home loans increased by 12 million euros, leasing increased by 2 million euros, business loans increased by 1 million euros and consumer financing loan portfolio increased by 1 million euros. Over the year, loan portfolio has grown by 10%.
  • In July, the loan impairment cost was 0.4 million euros.
  • Compared to the first seven months of last year, the bank's net income decreased by 3% and expenses have increased by 20%.
  • In July, the bank earned net profit of 3.1 million euros. In the first seven months of the year, the bank has earned a net profit of 20.2 million euros, that is 12% less than in the same period last year.
  • In July, Coop Pank's return on equity was 18.4% and the cost-income ratio was 47%.

Comment by Paavo Truu, Member of the Management Board and CFO of Coop Pank:

"Coop Pank's customer base is fast approaching 200,000 customers, which shows that Estonians have well accepted the domestic bank and are actively using its advantages.

On the loan market, home loans and car leasing have shown the highest activity across the market. Coop Pank has significantly increased its market share in household loans - in the first half of 2024, Coop Pank has made more than 15% of the growth of the entire market and even larger share of the growth of the leasing market. The good growth of home loans and leasing has continued as well in July. On the side of business loans, market growth is more modest, and primarily financing transactions from one bank to another take place.

In the money markets, the downward trend of interest rates is predicted to continue, which will consistently lower both the Euribore and term deposit interest rates.

The growth of business volumes in all business lines and the continued good quality of the loan portfolio resulted in a strong net profit of 3.1 million euros in July. Coop Pank's return on equity in July was 18.4% and the cost-income ratio was 47%, which exceed the bank's long-term goals."

More detailed financial reports of Coop Pank are available at:https://www.cooppank.ee/en/financial-reports

Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. The number of clients using Coop Pank for their daily banking reached 197,700. Coop Pank aims to put the synergy generated by the interaction of retail business and banking to good use and to bring everyday banking services closer to people's homes. The strategic shareholder of the bank is the domestic retail chain Coop Eesti, comprising of 320 stores.

Additional information:
Paavo Truu
CFO
Phone: +372 5160 231
E-mail: paavo.truu@cooppank.ee


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.